Clinical trial · Observational
Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
RIM - Rituximab in Maintenance
NCT02536664CI-TRIAL-00065696completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is a non-interventional study with a duration of approximately 24 months per participant to investigate the therapeutic efficiency, safety and treatment regimens of Rituximab maintenance therapy in daily routine in participants with previously untreated, relapsed or refractory cluster of differentiation 20 (CD20)-positive follicular lymphoma (FL) in clinical practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Rituximab | Drug | Rituximab | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- First-line Stratum
- description
- Participants who were untreated and decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
- interventionNames
- Drug: Rituximab
- label
- Relapsed/Refractory Stratum
- description
- Participants who relapsed after treatment with chemotherapeutic regimens with or without Rituximab and were decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
- interventionNames
- Drug: Rituximab
Primary outcomes (1)
- measure
- Percentage of Participants Who Were Alive and Free From Progressive Disease
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age over 18 years * Previously untreated, relapsed or refractory CD 20-positive FL * Responding to rituximab containing induction therapy (complete response \[CR\] or partial response \[PR\]) * To receive rituximab maintenance therapy (decision taken by doctor prior to and independent of this non-interventional study) * No ineligibility for rituximab Exclusion Criteria: Not Applicable (NA)
References
Publications (0)
Data not yet available
No reference posted for this study.